4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2025)
Historic Liabilities and Shareholders Equity for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $424.0 million.
- 4D Molecular Therapeutics' Liabilities and Shareholders Equity fell 2980.76% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 1003.63%. This contributed to the annual value of $560.4 million for FY2024, which is 6487.17% up from last year.
- Per 4D Molecular Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $424.0 million for Q3 2025, which was down 2980.76% from $473.6 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $629.9 million during Q1 2024, with a 5-year trough of $240.6 million in Q3 2021.
- Moreover, its 5-year median value for Liabilities and Shareholders Equity was $352.5 million (2023), whereas its average is $390.3 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Liabilities and Shareholders Equity skyrocketed by 15812.7% in 2024 and then crashed by 2980.76% in 2025.
- 4D Molecular Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $353.5 million in 2021, then dropped by 25.92% to $261.8 million in 2022, then grew by 29.81% to $339.9 million in 2023, then skyrocketed by 64.87% to $560.4 million in 2024, then dropped by 24.34% to $424.0 million in 2025.
- Its Liabilities and Shareholders Equity was $424.0 million in Q3 2025, compared to $473.6 million in Q2 2025 and $515.7 million in Q1 2025.